This panel showcases the perspectives of experienced M&A attorneys and consultants as they review lessons learned in the life sciences sector and explore the outlook for the transactional landscape. The pandemic brought on unexpected challenges sending global economies into hibernation and causing dealmaking to stall-with the aggregate M&A deal value for the life sciences sector. M&A activity was affected as buyers, sellers, and target businesses pivoted to crisis management issues rather than strategic transactions. We'll discuss how the life sciences sector can leverage insights from past M&A deals to capitalize innovation and provide pathways to thrive moving forward.

Pricing: $49